Utilization of FAERS Public Dashboard to Identify Letermovir-Associated Safety Signals

Abstract

Get full access to this article

View all access options for this article.

References

Marty

Ljungman

Chemaly

, et al Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. New Eng J Med. 2017;377(25):2433-2444.

Limaye

Budde

Humar

, et al Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial. JAMA. 2023;330(1):33-42. doi:10.1001/jama.2023.9106

Fukuda

Hattori

Ohkubo

Watanabe

Maekawa

Real-world safety and effectiveness of Letermovir in patients undergoing allogenic hematopoietic stem cell transplantation: final results of post-marketing surveillance in Japan. Clin Drug Investig. 2024;44(7):527-540. doi:10.1007/s40261-024-01376-w

McCrea

Macha

Adedoyin

, et al Pharmacokinetic drug-drug interactions between Letermovir and the immunosuppressants cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil. J Clin Pharmacol. 2019;59(10):1331-1339. doi:10.1002/jcph.1423

Maples

Maloy

Devlin

, et al Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients. Bone Marrow Transplant. 2020;55(8):1687-1689. doi:10.1038/s41409-020-0785-9

Marciano

Seago

Dillaman

Ross

Veltri

Cumpston

Evaluation of the pharmacokinetic interaction between letermovir and tacrolimus in allogeneic hematopoietic cell transplantation recipients. Transplant Cell Ther. 2022;28(7):371.e1-371.e4. doi:10.1016/j.jtct.2022.03.028

Burger

Nijboer

Ghobreyal

, et al Drug-drug interaction management with the novel anti-cytomegalovirus agents Letermovir and Maribavir: guidance for clinicians. Clin Pharmacokinet. 2024;63(11):1529-1546. doi:10.1007/s40262-024-01437-5

Hedvat

Choe

Salerno

, et al Managing the significant drug-drug interaction between tacrolimus and letermovir in solid organ transplant recipients. Clin Transplant. 2021;35(3):e14213. doi:10.1111/ctr.14213

Descourouez

Mandelbrot

Odorico

Jorgenson

MR.

LCP-tacrolimus requires a similar empiric dose adjustment to immediate-release tacrolimus when given concomitantly with Letermovir for cytomegalovirus primary prophylaxis. Ann Pharmacother. 2024;58(8):870-871. doi:10.1177/10600280231208430